The global esophageal cancer drugs market is expected to grow at a significant CAGR during the forecast period (2021-2027). Esophageal cancer drugs are commonly used to treat adenocarcinoma, squamous cell carcinoma, and other kinds of esophageal cancer. Men are more likely than women to be diagnosed with esophageal cancer. The majority of cases of esophageal cancer are seen in low-income countries. Malawi, Mongolia, Kenya, and Bangladesh, had the highest risk of esophageal cancer, according to a World Cancer Research Fund (WCRF) International report from 2018. Esophageal cancer can be treated with chemo, immunotherapy, and targeted medication therapies. Some medications, such as the XELIRI combination of Capecitabine and Irinotecan Hydrochloride, are used in combination and have been approved by the Food and Drug Administration (FDA).
Increased research and development, as well as the introduction of novel products by key players, are projected to propel the global esophageal cancer drugs market forward during the forecast period. The global market for esophageal cancer drugs is predicted to rise rapidly due to increased research and development for new drug discovery for the treatment of esophageal cancer. For instance, researchers at Case Western Reserve University in the US discovered in February 2019 that blocking two molecular pathways that communicate signals inside cancer cells can diminish esophageal adenocarcinoma (EAC), the most frequent esophageal malignancy in the US. These data point to JNK/TGF-beta-targeted therapy as a novel esophageal cancer drugs option.
To Request a Sample of our Report on Global Esophageal Cancer Drugs Market: https://www.omrglobal.com/request-sample/esophageal-cancer-drugs-market
Furthermore, age, gender, tobacco, alcohol, Barrett’s oesophagus, obesity, and achalasia are all substantial risk factors for esophageal cancer. During the forecast period, these factors are projected to boost demand for the global esophageal cancer drugs market. Achalasia patients, had a 50-fold higher risk of esophageal squamous cell carcinoma than the general population. Achalasia affects 9 to 10 persons in every 100,000 people around the globe.
Market Coverage
· The market number available for – 2020-2027
· Base year- 2020
· Forecast period- 2021-2027
· Segment Covered
· Regions Covered- Globally
· Competitive Landscape: Amgen Inc., Eli Lilly and Company, F. Hoffmann-La Roche, Bristol-Myers Squibb Company among others.
(Get 15% Discount on Buying this Report)
A full Report of Global Esophageal Cancer Drugs Market is Available at: https://www.omrglobal.com/industry-reports/esophageal-cancer-drugs-market
Global Esophageal Cancer Drugs Market by Segment
By Therapy Type
• Chemotherapy
· Docetaxel
· Irinotecan
· Trifluridine and Tipiracil
· Carboplatin and Paclitaxel
· Cisplatin and 5-fluorouracil
· Cisplatin with Capecitabine
By Distribution Channel
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
Global Esophageal Cancer Drugs Market by Region
North America
· United States
· Canada
Europe
· UK
· Germany
· Spain
· France
· Italy
· Rest of Europe
Asia-Pacific
· India
· China
· Japan
· South Korea
· Rest of APAC
Rest of the World
Reasons to buy from us –
1. We cover more than 15 major industries, further segmented into more than 90 sectors.
2. More than 120 countries are for analysis.
3. Over 100+ paid data sources mined for investigation.
4. Our expert research analysts answer all your questions before and after purchasing your report.
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.
Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 7803040404
(This release has been published on Global Market Post. Global Market Post is not responsible for any content included in this release.)
